NasdaqGS - Nasdaq Real Time Price USD

Treace Medical Concepts, Inc. (TMCI)

10.40

+0.10

(+0.97%)

At close: April 26 at 4:00 PM EDT

10.45

+0.05

(+0.48%)

After hours: April 26 at 6:05 PM EDT

Treace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA Tour

Partnership to help pickleball players of all levels with bunions and related midfoot deformities to “get back on their feet” and out on the courtDALLAS and PONTE VEDRA, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- The Professional Pickleball Association (PPA) Tour and Treace Medical Concepts, Inc. (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedur

GlobeNewswire 3 days ago
Treace to Present at Bank of America Health Care Conference

Wednesday, May 15, 2024, at 2:20 pm Pacific TimePONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fires

GlobeNewswire 10 days ago
Treace Announces First Annual National Bunion Day

Focus on Foot Health Issue Affecting Millions of People Includes Outreach and Education Efforts to Build Awareness, Reduce Stigma and Correct Misconceptions About This Common Bone DeformityPONTE VEDRA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Pro

GlobeNewswire 11 days ago
Treace to Report First Quarter 2024 Financial Results

Company to Host Conference Call on Tuesday, May 7, 2024 at 4:30 pm ETPONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of trading

GlobeNewswire 18 days ago
Treace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestone

Treace 100K+ Lapiplasty® Patients Treace Medical Celebrates 100K+ Lapiplasty® Patients Lauren - Lapiplasty® Patient and Collegiate Diver Lauren, Lapiplasty® Patient and Collegiate Diver Lauren - Lapiplasty® Patient Lapiplasty® Patient Lauren Working Out Treace Lapiplasty® Procedure Lapiplasty® - The Future of Bunion Surgery is Here Treace Further Expands Focus on Bunion Deformity Education by Sponsoring First-Ever National Bunion Day in the U.S. on April 16, 2024 Launches New “Future You” Patien

GlobeNewswire last month
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance

PONTE VEDRA, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided 2024 guidance. Recent Highlights Revenue of $62.2 million in fourth quarte

GlobeNewswire last month
Treace to Report Fourth Quarter and Full-Year 2023 Financial Results

Company to Host Conference Call on Tuesday, February 27, 2024 at 4:30 pm ETPONTE VEDRA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2023 after

GlobeNewswire 2 months ago
Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

PONTE VEDRA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions were presented in a podium

GlobeNewswire 2 months ago
Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference

Company Previews New SpeedPlate™ Configurations, Announces Full Commercial Release of its Micro-Lapiplasty™ System and Limited Clinical Release of its Mini-Adductoplasty™ System and RedPoint™ Patient-Specific InstrumentationPONTE VEDRA, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship

GlobeNewswire 2 months ago
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue

Company to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:45 pm Pacific TimePONTE VEDRA, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 20

GlobeNewswire 3 months ago
Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference

Tuesday, January 9, 2024, at 3:45 pm Pacific TimePONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on T

GlobeNewswire 4 months ago
Treace Medical Concepts Reports Third Quarter 2023 Financial Results

PONTE VEDRA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights: Revenue of $40.8 million in the third quarter, a 23% increase over same period last ye

GlobeNewswire 5 months ago
Treace to Present at Stifel 2023 Healthcare Conference

PONTE VEDRA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on T

GlobeNewswire 5 months ago
Treace to Report Third Quarter 2023 Financial Results

Company to Host Conference Call on Thursday, November 9, 2023 at 4:30 pm ETPONTE VEDRA, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Thursday, Nov

GlobeNewswire 6 months ago
Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

PONTE VEDRA, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ clinical study at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Me

GlobeNewswire 7 months ago
Treace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. Patent

PONTE VEDRA, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, is pleased to announce the United States Patent and Trademark Office’s (USPTO) forthcoming issuance of U.S. Patent No. 11,771,467, to publish on October 3, 2023 (the ‘467 Patent). “Our

GlobeNewswire 7 months ago
Treace Medical Concepts Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related Procedures

Further Expands Market Opportunity to Include Hammertoe Correction Company Receives 510(k) Clearance for Second-Generation SpeedPlate™ Implant Fixation Platform Ahead of Full Market Launch in Fourth Quarter of 2023 PONTE VEDRA, Fla., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D

GlobeNewswire 7 months ago
Treace Announces Participation in the 21st Annual Morgan Stanley Global Healthcare Conference

PONTE VEDRA, Fla., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the 21st Annual Morgan Stanley Global Heal

GlobeNewswire 8 months ago
Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace’s marketing effo

GlobeNewswire 8 months ago
Treace Medical Concepts Reports Second Quarter 2023 Financial Results

PONTE VEDRA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights: Revenue of $42.0 million in the second quarter of 2023, a 40% increase over same period la

GlobeNewswire 8 months ago

Performance Overview

Return	TMCI	S&P 500
YTD	-18.43%	+6.92%
1-Year	-60.02%	+25.26%
3-Year	-57.55%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Treace Medical Concepts, Inc. (TMCI)

Treace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA Tour

Treace to Present at Bank of America Health Care Conference

Treace Announces First Annual National Bunion Day

Treace to Report First Quarter 2024 Financial Results

Treace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestone

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance

Treace to Report Fourth Quarter and Full-Year 2023 Financial Results

Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue

Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference

Treace Medical Concepts Reports Third Quarter 2023 Financial Results

Treace to Present at Stifel 2023 Healthcare Conference

Treace to Report Third Quarter 2023 Financial Results

Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

Treace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. Patent

Treace Medical Concepts Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related Procedures

Treace Announces Participation in the 21st Annual Morgan Stanley Global Healthcare Conference

Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

Treace Medical Concepts Reports Second Quarter 2023 Financial Results

Performance Overview